-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 19, Huadong Medicine’s wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co.
, Ltd.
(referred to as "Zhongmei Huadong") and Huadong Medicine Investment Holdings (Hong Kong) Co.
, Ltd.
(referred to as “Huadong Medicine Investment Holdings”) and Ashvattha Therapeutic Signed an equity investment agreement and product exclusive license agreement
.
According to the agreement, Huadong Pharmaceutical Investment Holdings will invest in phased investment subscriptions for the Series B preferred shares issued by Ashvattha
Ashvattha is an innovative biopharmaceutical company specializing in hydroxy dendrimer therapies (HDTs), founded by three scientists, namely: Dr.
Kannan Rangaramanujam, who is a special appointment at the Wilmer Eye Institute of Johns Hopkins School of Medicine Professor and co-director of the Nanomedicine Center, with more than 15 years of experience in the development and verification of dendrimer platforms; Sujatha Kannan, MD, Professor of Anesthesiology, Critical Care Medicine and Pediatrics at Johns Hopkins University School of Medicine, her research focus It uses nanotechnology for imaging and targeted therapy of pediatric brain diseases; Dr.
Jeffrey Cleland, who is a PhD in chemical engineering from MIT, has more than ten years of experience in new drug research and development
.
Currently, Ashvattha is developing new therapies that target and change specific cells in the diseased tissue area
.
The company's platform technology, hydroxy dendrimer (HD), has obtained an exclusive license from Johns Hopkins University
This time, Huadong Medicine introduced 8 products under research from Ashvattha Company, covering the treatment fields of tumors, metabolic comorbidities and inflammations
.
Among them, one product has entered Phase 2 clinical trials in the United States, and two products are scheduled to submit IND applications in the United States in the first quarter of 2022
According to the press release, the hydroxy dendrimer therapy developed by Ashvattha has good disease cell targeting.
It can be administered systemically through oral, injection, etc.
, while selectively targeting the reactive cells of disease tissues, providing local sustained effects.
, Benefit patients
.
In addition, dendrimers can pass through tissue barriers (such as blood-brain barrier, blood-retinal barrier) for the treatment of various diseases, and have the advantages of good safety, low off-target toxicity, and large-scale production
Huadong Medicine pointed out in the press release that Ashvattha’s technology belongs to nanomedicine and nanomaterials.
Its unique HD platform is currently the only hydroxy dendrimer platform capable of producing highly selective drugs in the world.
The tissue barrier has the potential to develop a variety of therapeutic drugs
.
These products introduced this time will provide doctors and patients with more accurate and scientific diagnosis and treatment and medication options after they are launched in the future
Reference materials:
Reference materials:[1] Huadong Medicine and Ashvattha of the United States signed an equity investment agreement and product exclusive license agreement.
[1] Huadong Medicine and Ashvattha of the United States signed an equity investment agreement and product exclusive license agreement.
Retrieved Oct 19, 2021, from https://mp.
weixin.
qq.
com/s/9nqIG3_I-rmqY2cTQDPV0w
